Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)

Inclusion Criteria:

- The subject was randomized into Study M10-855 and completed through Week 26 in that
study.

- The subject is receiving one or more antipsychotic medications.

Exclusion Criteria:

- Additional history collected during participation in Study M10-855 provides evidence
that, in the investigator's judgement, the subject does not have schizophrenia.

- The subject experienced an adverse event or abnormal finding during physical
examination, vital signs, laboratory profile, and/or electrocardiogram (ECG)
measurements in Study M10-855 that indicates the subject is likely to become medically
unstable during the current study.

- The subject is currently taking or is expected to be prescribed any excluded
medication without the approval of AbbVie medical monitor.

- The subject is currently enrolled in, or plans to participate in, another
interventional study during the course of this trial.